US Stock MarketDetailed Quotes

CERO CERo Therapeutics

Watchlist
  • 0.918
  • -0.022-2.37%
Close May 24 16:00 ET
  • 0.920
  • +0.002+0.24%
Post 19:55 ET
13.82MMarket Cap-1854P/E (TTM)

CERo Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q1)Mar 31, 2022
(FY)Dec 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
62.14%-1.44M
-16.00%-11.71M
-3.79M
-10.09M
Net income from continuing operations
30.64%-2.44M
-11.28%-11.83M
---3.52M
---10.63M
Operating gains losses
339.17%36.66K
96.23%-36.99K
---15.33K
---980.31K
Depreciation and amortization
8.81%273.58K
45.87%1.07M
--251.43K
--735.47K
Change In working capital
203.94%663.27K
-363.45%-1.3M
---638.13K
--492.34K
-Change in prepaid assets
167.91%90.1K
-49.26%49.59K
---132.68K
--97.73K
-Change in payables and accrued expense
299.99%733.03K
-210.47%-761.42K
---366.53K
--689.26K
-Change in other current liabilities
-15.07%-159.86K
-98.63%-585.25K
---138.92K
---294.65K
Cash from discontinued investing activities
Operating cash flow
62.14%-1.44M
-16.00%-11.71M
---3.79M
---10.09M
Investing cash flow
Cash flow from continuing investing activities
-13.33%-694.23K
-409.98K
-612.57K
Net PPE purchase and sale
----
-13.33%-694.23K
---409.98K
---612.57K
Cash from discontinued investing activities
Investing cash flow
----
-13.33%-694.23K
---409.98K
---612.57K
Financing cash flow
Cash flow from continuing financing activities
5.17K
-90.66%5.63K
0
60.26K
Net issuance payments of debt
--0
----
----
----
Net preferred stock issuance
--0
----
----
----
Proceeds from stock option exercised by employees
--5.17K
-90.66%5.63K
--0
--60.26K
Cash from discontinued financing activities
Financing cash flow
--5.17K
-90.66%5.63K
--0
--60.26K
Net cash flow
Beginning cash position
-64.51%6.82M
-35.65%19.22M
--19.22M
--29.86M
Current changes in cash
65.95%-1.43M
-16.45%-12.4M
---4.2M
---10.65M
End cash Position
-64.11%5.39M
-64.51%6.82M
--15.01M
--19.22M
Free cash flow
65.83%-1.44M
-15.85%-12.4M
---4.2M
---10.71M
Currency Unit
USD
USD
USD
USD
(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q1)Mar 31, 2022(FY)Dec 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 62.14%-1.44M-16.00%-11.71M-3.79M-10.09M
Net income from continuing operations 30.64%-2.44M-11.28%-11.83M---3.52M---10.63M
Operating gains losses 339.17%36.66K96.23%-36.99K---15.33K---980.31K
Depreciation and amortization 8.81%273.58K45.87%1.07M--251.43K--735.47K
Change In working capital 203.94%663.27K-363.45%-1.3M---638.13K--492.34K
-Change in prepaid assets 167.91%90.1K-49.26%49.59K---132.68K--97.73K
-Change in payables and accrued expense 299.99%733.03K-210.47%-761.42K---366.53K--689.26K
-Change in other current liabilities -15.07%-159.86K-98.63%-585.25K---138.92K---294.65K
Cash from discontinued investing activities
Operating cash flow 62.14%-1.44M-16.00%-11.71M---3.79M---10.09M
Investing cash flow
Cash flow from continuing investing activities -13.33%-694.23K-409.98K-612.57K
Net PPE purchase and sale -----13.33%-694.23K---409.98K---612.57K
Cash from discontinued investing activities
Investing cash flow -----13.33%-694.23K---409.98K---612.57K
Financing cash flow
Cash flow from continuing financing activities 5.17K-90.66%5.63K060.26K
Net issuance payments of debt --0------------
Net preferred stock issuance --0------------
Proceeds from stock option exercised by employees --5.17K-90.66%5.63K--0--60.26K
Cash from discontinued financing activities
Financing cash flow --5.17K-90.66%5.63K--0--60.26K
Net cash flow
Beginning cash position -64.51%6.82M-35.65%19.22M--19.22M--29.86M
Current changes in cash 65.95%-1.43M-16.45%-12.4M---4.2M---10.65M
End cash Position -64.11%5.39M-64.51%6.82M--15.01M--19.22M
Free cash flow 65.83%-1.44M-15.85%-12.4M---4.2M---10.71M
Currency Unit USDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg